Apoptosis and prognosis in cancer: Rationale and relevance

Journal of the Royal College of Surgeons of Edinburgh

Volumn 45, Issue 4, 2000, Pages 211-219

  Langlois, N E I ^a   Eremin, O ^a   Heys, S D ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Apoptosis; Neoplasia; Prognostic factors

Indexed keywords

CYSTEINE PROTEINASE; DNA; MYC PROTEIN; PROTEIN BCL 2; PROTEIN P53; ANTINEOPLASTIC AGENT;

APOPTOSIS; CAENORHABDITIS ELEGANS; CANCER GROWTH; CARCINOGENESIS; CELL COUNT; CELL CYCLE; CELL STRUCTURE; DIAGNOSTIC VALUE; DISEASE MARKER; DNA CLEAVAGE; ELECTRON MICROSCOPY; HISTOPATHOLOGY; HUMAN; MICROSCOPY; NONHUMAN; ONCOGENE C MYC; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE; ANEUPLOIDY; ANIMAL CELL; CANCER; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; GENE MUTATION; MALIGNANT TRANSFORMATION; METASTASIS; MITOSIS INDEX; MOUSE; NEUROBLASTOMA; PROTEIN EXPRESSION; RAT; TUMOR CELL; TUMOR GROWTH; TUMOR REGRESSION;

ANIMALS; APOPTOSIS; COLORECTAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; NEOPLASMS; PROGNOSIS; RATS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034958742     PISSN: 00358835     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. Apoptosis, oncosis and necrosis
2. Shrinkage necrosis: A distinct mode of cellular death
3. Shrinkage necrosis of adrenal cortical cells
4. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
5. Programmed cell death: Necrosis versus apoptosis
6. Apoptosis and disease
7. Large-scale normal cell death in the developing rat kidney and its reduction by epidermal growth factor
8. Cell death: Current difficulties in discriminating apoptosis from necrosis in the context of pathological processes in vivo
9. Apoptosis
10. Apoptosis: Its significance in cancer and cancer therapy
11. Social controls on cell survival and cell death
12. Cell death: The significance of apoptosis
13. Tantigen is bound to a host protein in SV40-transformed cells
14. A deadly inheritance
15. P53, guardian of the genome
16. P53 function and dysfunction
17. P53 immunohistochemistry: A word of caution
18. Mechanism of p53 degradation
19. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life
20. P53 in tumour pathology: Can we trust immunohistochemistry? - Revisited!
21. P53 in tumour pathology: Can we trust immunocytochemistry?
22. The p53 pathway
23. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death
24. The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation
25. Bcl-2 and bak may play a pivotal role in sodium butyrate-induced apoptosis in colonic epithelial cells; however, overexpression of bcl-2 does not protect against bak-mediated apoptosis
26. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
27. Bcl-2 in cancer, development and apoptosis
28. Regulation of apoptosis by Bcl-2 and its related proteins; immunochemical challenges and therapeutic implications
29. Bcl-2/Bax: A rheostat that regulates an antioxidant pathway and cell death
30. Regulators of death
31. Bcl-2 expression in adult and embryonic non-haematopoietic tissues
32. What is the value of bcl-2 protein detection for histopathologists?
33. Death-defying yeast identify novel apoptosis genes
34. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis
35. The role of c-myc in cell growth
36. Induction of apoptosis in fibroblasts by c-myc protein
37. Oncogenic activity of the c-Myc protein requires dimerization with Max
38. Mapping of two genes encoding members of a distinct subfamily of Max interacting proteins: Mad to human chromosome 2 and mouse chromosome 6, and Mxi1 to human chromosome 10 and mouse chromosome 19
39. Mad-Max transcriptional repression is mediated by tertiary complex formation with mammalian homologs of yeast repressor Sin3
40. Mxil, a protein that specifically interacts with Max to bind Myc-Max recognition sites
41. New light on myc and myb
42. Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with myc
43. Repression of Myc-Ras cotransformation by Mad is mediated by multiple protein-protein interactions
44. Cell death in cancer and development
45. Braking the ICE
46. Mitochondrial proliferation and paradoxical membrane depolariation during terminal differentiation and apoptosis in a human colon carcinoma cell line
47. Apoptosis: Suicide, execution or murder?
48. Apoptosis and the cell cycle
49. Why are mitochondria involved in apoptosis?
50. The molecular biology of apoptosis
51. Apoptosis
52. Molecular control of life and death
53. A cellular poison cupboard
54. Patterns of death
55. Defining apoptosis
56. Apoptosis is a major mode of cell death caused by ischaemia/reperfusion injury to the rat intestinal epithelium
57. Death by any other name
58. Counting apoptosis - Why and how?
59. The extent of apoptosis in different types of high grade prostatic carcinoma
60. The frequency of apoptosis correlates with the prognosis of Gleason grade 3 adenocarcinoma of the prostate
61. Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas
62. Apoptosis in breast cancer as related to histopathological characteristics and prognosis
63. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis
64. Astro research fellowship: Apoptosis as a predictor of tumour response to radiation in stage IB cervical carcinoma
65. Apoptosis, cell proliferation and expression of bcl-2 and Bax in gastric carcinomas: Immunohistochemical and clinicopathological study
66. Counting of apoptotic cells: A methodological study in invasive breast cancer
67. Mitosis counting-II
68. Association between the apoptotic index and established prognostic parameters in endometrial adenocarcinoma
69. Tumour type is a determinant of susceptibility to apoptosis
70. Correlation of p53 protein expression with apoptotic incidence in colorectal neoplasia
71. Apoptosis in renal cell carcinoma
72. Regulation of cell number in the mammalian gastrointestinal tract: The importance of apoptosis
73. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas
74. Tumour growth fraction and apoptosis in salivary gland acinic cell carcinomas. Prognostic implications of Ki-67 and bcl-2 expression and of in situ end labelling (TUNEL)
75. Cellular death in neuroblastoma: In situ correlation of apoptosis and bcl-2 expression
76. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostatic carcinoma recurrence after surgery
77. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma
78. Ultrastructural detection of DNA strand breaks in apoptotic neural cells by in situ end-labelling techniques
79. Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation
80. In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states
81. False positive staining in the TUNEL assay to detect apoptosis in liver and intestine is caused by endogenous nucleases and inhibited by diethyl pyrocarbonate
82. The two in situ techniques do not differentiate between apoptosis and necrosis but rather reveal distinct patterns of DNA fragmentation in apoptosis
83. In situ end-labelling, light microscopic assessment and ultrastructure of apoptosis in lung carcinoma
84. The clinical assessment of proliferation and growth in human tumours: Evaluation of methods and applications as prognostic variables
85. Expression of mitoses per thousand cells and cell density in breast carcinomas
86. Apoptosis as a predictor of response to radiotherapy in cervical carcinoma
87. Can you count on the mitotic index?
88. Is histologic grading of colon carcinoma a valid procedure?
89. Assessment of cell proliferation in pathology - What next?
90. A critical evaluation of AgNOR counting in benign naevi and malignant melanoma
91. The influence of fixation delay on mitotic activity and flow cytometric cell cycle variables
92. Estimating mitotic activity in tumours
93. Changes in mitotic rate and cell cycle fractions caused by delayed fixation
94. What is an apoptotic index measuring? A commentary
95. Characterization of apoptosis in intestinal ischaemia-reperfusion injury - A light and electron microscopic study
96. Cell death and control of cell survival in the oligodendrocyte lineage
97. In vitro models of human colorectal cancer
98. Induction of immortality is an early event in malignant transformation of mammalian cells by carcinogens
99. Inhibition of apoptosis during development of colorectal cancer
100. Life, death and genomic change in perturbed cell cycles
101. P53-dependent apoptosis suppresses tumour growth and progression in vivo
102. The p53 tumour suppressor gene and tumour prognosis: Is there a relationship?
103. Reduced messenger RNA expression level of p21cipl in human colorectal carcinoma tissues and its association with p53 gene mutation
104. Overexpression of cyclin D1 and p53 associated with diesease recurrence in colorectal adenocarcinoma
105. Analysis of the cell population kinetics of transplanted tumours of widely differing growth rate
106. The chemotherapy of colon cancer can be longer be ignored
107. Lessons from hereditary colorectal cancer
108. A model for metastases formation
109. Rodent fibroblast tumours expressing human myc and ras genes: Growth, metastasis and endogenous oncogene expression
110. P53 mutations in primary colorectal adenocarcinomas and liver metastases
111. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
112. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient mice
113. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells
114. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
115. Apoptosis in antitumour strategies: Modulation of cell cycle or differentiation
116. Apoptosis induced by anticancer drugs
117. Apoptosis. Biochemical events and relevance to cancer chemotherapy
118. Apoptosis in colorectal carcinoma occurring in patients aged 45 years and under: Relationship to prognosis, mitosis, and immunohistochemical demonstration of p53, c-myc and bcl-2 proteins
119. Positive correlation between apoptotic and proliferative indices in gastrointestinal lymphomas of mucosa-associated lymphoid tissue (MALT)
120. Both cell proliferation and apoptosis increase with lesional grade in cervical neoplasia, but do not correlate with human papillomavirus type
121. Integrated control of cell proliferation and cell death by the c-myc oncogene
122. The grading and prognosis of carcinoma of the colon and rectum
123. Progressive increase of apoptosis in prostatic intraepithelial neoplasia and carcinoma
124. Review: Assessment of cell proliferation in histological material
125. Apoptosis in human adeocarcinoma HT29 cells induced by exposure to hypoxia
126. Life (and death) in a malignant tumour
127. Biology of tumour metastasis
128. Recent advances in the study of tumour invasion and metastasis
129. Molecular aspects of tumour cell invasion and metasis
130. Massive apoptosis detected by in situ DNA nick end labelling in neuroblastoma